Research programme: respiratory disease therapy - Aus Bio
Alternative Names: MD 990Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Aus Bio Limited
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Australia
- 19 Apr 2010 Preclinical development is ongoing Australia
- 12 May 2005 Preclinical trials in Respiratory tract disorders in Australia (unspecified route)